Interview with Dominique Amory, President, Lilly France
There is a lot of activity in the pharmaceutical industry and France is no exception especially having passed Germany as the major market of Europe over the past year which…
Address: 24 Boulevard Vital Bouhot
CS 50004
92521 Neuilly-sur-Seine Cedex
Tel: 01 55 49 34 34
Web: http://www.lilly.com/Pages/home.aspx
The Pharmaceutical company Lilly has been in France since 1962. This is the 4th subsidiary of Lilly after the United States, Japan and Germany.
Lilly France is the 16th French pharmaceutical company and has a turnover of 2.3 billion euros in 2008, including 1.6 billion under its manufacturing (factory Fegersheim).
Advancing medicine, contributing to major therapeutic advances, allowing everyone to live better and longer: this is the mission of the pharmaceutical company Lilly.
Eli Lilly and Company is a specialty pharmaceutical company entirely focused on innovation and committed to developing a portfolio of drugs to both the best and the first in their class, to allow patients to be healthier and live a longer and more active.
To do this, we use the results of recent medical studies in our laboratories pharmaceutical world. We are collaborating with eminent scientific organizations, and we appeal to the most advanced technological tools, while ensuring the high quality service to our customers.
Through internal programs and external initiatives, we intend to meet the most urgent medical needs. Lilly employs more than 40 450 people worldwide and markets its medicines in 143 countries. The company has major research and development centers in 9 countries and conducts clinical trials in over 50 countries.
Lilly’s drugs treat depression, schizophrenia, cancer, diabetes, osteoporosis and other disorders.
There is a lot of activity in the pharmaceutical industry and France is no exception especially having passed Germany as the major market of Europe over the past year which…
France’s minority government has forced through a Social Security & Healthcare Bill for 2026 containing EUR five billion in healthcare cuts. For the country’s beleaguered innovative pharma industry, this Bill…
At the helm of EG Labo (STADA Group), Tiago Bartolomeu is steering one of France’s leading accessible medicine players through a period of renewal and ambition. With a clear focus…
As CEO of Transgene, Alessandro Riva is steering the French biotech into a new era of cancer immunotherapy. Building on more than four decades of scientific excellence, Transgene is advancing…
Under Laurence Rodriguez’s leadership, GenSight Biologics is charting a bold path forward after a period of reset, advancing groundbreaking gene therapies for rare ophthalmic and mitochondrial diseases. She reflects on…
From Hungary to Poland and now France, Nienke Feenstra has navigated some of Europe’s most complex healthcare landscapes. Today, as GM of Takeda France, she reflects on the country’s scientific…
Curium is redefining how radiopharmaceuticals are developed, manufactured, and delivered to patients worldwide. Under the leadership of Ciril Faia, Curium International is advancing a new generation of diagnostic and therapeutic…
Born from a serendipitous scientific discovery in Montpellier, Abivax has evolved into one of France’s most promising global biotechs. Led by CEO Marc de Garidel, the company is harnessing its…
Created in the wake of COVID-19, the Agence de l’Innovation en Santé (AIS), part of the Secrétariat Général pour l’investissement – a Prime Minister department, has rapidly positioned itself at…
LEO Pharma – a global heavyweight in the dermatology field – is undergoing a period of renewal, combining a stronger focus on innovation with a cultural transformation aimed at greater…
Francois LAMY, Vice President of AFM-Téléthon and father of a child with Duchenne muscular dystrophy, shares how the organisation grew from a family-led initiative into a major force in rare…
Genopole stands as one of France’s leading bioclusters, seamlessly integrating world-class research, entrepreneurship, and industrial engagement to support over 80 companies across health and the bioeconomy. Under Gilles Trystram’s leadership,…
Pascal Houdayer, recently appointed CEO and the first non-family investor of Boiron, brings three decades of global leadership experience to one of France’s most iconic healthcare enterprises. In this conversation,…
See our Cookie Privacy Policy Here
